BARD1 LIFE SCIENCES LIMITED has not announced any capital raises, but we are collecting interest for future raises.
1. Create Account
Complete your onboarding digitally in less than 3 minutes.
2. View Terms
View the full term sheet for the capital raise.
3. Bid for Allocation
Submit and track your bid online.
7 November 2018
13 June 2019
BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.
Health Care Services
431 Roberts Rd, Subiaco WA 6008, Australia
Fresh Equities does not have BARD1 LIFE SCIENCES LIMITED quarterly cash flows data.
Fresh Equities does not have BARD1 LIFE SCIENCES LIMITED directors data.
Fresh Equities does not have BARD1 LIFE SCIENCES LIMITED announcements data.
Fresh Equities does not have BARD1 LIFE SCIENCES LIMITED news data.